+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neurological Biomarkers Market - Global Forecast 2026-2032- Product Image
Neurological Biomarkers Market - Global Forecast 2026-2032- Product Image
Sale

Neurological Biomarkers Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5454976
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neurological Biomarkers Market is projected to reach USD 9.88 Billion in 2026. It is expected to continue growing at a CAGR of 13.90%, reaching USD 21.74 Billion by 2032.

Neurological biomarkers are measurable indicators of disease biology, treatment response, or risk across conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, traumatic brain injury, stroke, and rare neurodegenerative disorders. The field is moving beyond specialist neuroimaging and cerebrospinal fluid testing toward scalable blood-based biomarkers, digital biomarkers, neurophysiology, genomics, proteomics, metabolomics, and AI-enabled image analytics.

Demand is reinforced by the global burden of neurological disease. The World Health Organization reported in 2024 that neurological conditions affect more than 3 billion people worldwide, while dementia affects more than 55 million people and epilepsy affects around 50 million. These epidemiological pressures are elevating neurological biomarkers from research tools to essential infrastructure for earlier diagnosis, patient stratification, clinical trial enrichment, and monitoring of disease progression.

The opportunity is strongest where validated biomarkers reduce diagnostic uncertainty, shorten clinical development timelines, and support precision neurology. Blood-based Alzheimer’s biomarkers, neurofilament light chain for neuroaxonal injury, amyloid and tau PET, advanced MRI, EEG-based indicators, and digital motor and cognitive measures are becoming central to clinical and commercial strategies.

Transformative Shifts in the Neurological Biomarkers Landscape

The neurological biomarkers landscape is being reshaped by three structural shifts: the move from late-stage diagnosis to earlier risk detection, the shift from single-modality testing to multi-omics and multimodal data integration, and the transition from research-grade assays to clinically deployable diagnostics. These shifts are driven by the need to detect disease biology before irreversible neurodegeneration and to match patients with targeted therapies.

Alzheimer’s disease is a leading example. Disease-modifying therapies that require confirmation of amyloid pathology have increased the need for PET, CSF, and emerging plasma biomarkers, while also strengthening demand for objective monitoring of safety and treatment response. In multiple sclerosis and traumatic brain injury, neurofilament light chain is gaining traction as a marker of neuronal injury, while digital biomarkers are expanding continuous assessment beyond episodic clinic visits.

Commercial differentiation is increasingly tied to analytical validity, clinical validity, clinical utility, regulatory readiness, payer evidence, and interoperability with electronic health records and decentralized trial platforms. Organizations that combine biomarker performance with workflow integration are better positioned than those offering isolated assays.

Cumulative Impact of Artificial Intelligence on Neurological Biomarkers

Artificial intelligence is accelerating neurological biomarker discovery and deployment by improving pattern recognition in imaging, electrophysiology, speech, gait, cognition, and wearable sensor data. AI models can help identify subtle changes in MRI, PET, retinal imaging, EEG, and digital behavior streams that may be difficult to detect through conventional clinical review.

The regulatory environment is also maturing. The U.S. FDA’s public inventory of AI/ML-enabled medical devices had surpassed 950 authorized devices by 2024, with radiology representing the largest category, indicating broad acceptance of AI-assisted interpretation when supported by evidence. In neurology, AI is most valuable when it enhances reproducibility, reduces reader variability, improves triage, and supports longitudinal measurement.

The cumulative impact is a shift from biomarker measurement to biomarker intelligence. However, leaders must manage model bias, data provenance, cybersecurity, explainability, and post-market performance monitoring. AI-enabled neurological biomarkers will gain trust fastest when trained on diverse datasets and validated prospectively across populations, devices, and care settings.

Key Regional Insights for Neurological Biomarkers

North America remains a leading region for neurological biomarker innovation due to strong academic medical centers, active clinical trial infrastructure, established regulatory pathways, and adoption of advanced neuroimaging and molecular diagnostics. The United States anchors commercialization through FDA engagement, payer evidence development, and specialty neurology networks, while Canada contributes through neuroscience research programs, public health data assets, and population-level research infrastructure.

Europe is characterized by coordinated research, biobanks, and regulatory rigor under frameworks such as the In Vitro Diagnostic Regulation and General Data Protection Regulation. The European Union’s emphasis on health data governance supports high-quality evidence generation, while the United Kingdom, Germany, France, Italy, and Spain remain important centers for clinical research, diagnostics adoption, dementia programs, and neurodegenerative disease studies.

Asia-Pacific is expanding as China, Japan, India, South Korea, and Australia invest in neuroscience, genomics, AI health technologies, and aging-related care. Latin America, led by Brazil and Mexico, shows rising demand for neurological diagnostics but continues to face access, reimbursement, and specialist availability constraints. The Middle East, especially GCC healthcare hubs, is building tertiary neurology, precision medicine, and digital health capacity, while Africa presents long-term potential through improved diagnostics, research partnerships, workforce development, and scalable point-of-care approaches.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, demand for neurological biomarkers is shaped by population growth, expanding private healthcare, and increasing attention to dementia, stroke, epilepsy, and neurodevelopmental disorders, although access to PET imaging, advanced MRI, and specialized laboratories remains uneven across member states. The GCC is investing in tertiary care, precision medicine, genomic initiatives, and digital health infrastructure, creating a favorable environment for high-value neurological diagnostics in urban health systems and specialist centers.

The European Union offers one of the most structured environments for biomarker evidence generation, supported by multicountry research programs, biobanks, harmonized regulatory expectations, and strong data protection requirements. BRICS economies combine high disease burden with expanding diagnostic capacity, making affordability, local clinical validation, workforce development, and scalable blood-based assays critical to broader adoption.

G7 markets represent the strongest concentration of reimbursement systems, pharmaceutical R&D, advanced imaging infrastructure, and specialty neurology capacity, supporting faster translation of validated neurological biomarkers into clinical and trial workflows. NATO countries overlap significantly with high-income markets where traumatic brain injury research, veteran brain health, secure health data systems, and resilient medical infrastructure can influence biomarker deployment.

Key Country Insights for Neurological Biomarker Adoption

The United States leads in commercialization, FDA interactions, clinical trial activity, advanced imaging, laboratory-developed testing, and payer-driven evidence requirements, while Canada provides strong neuroscience research and public health data capabilities. Mexico and Brazil are important Latin American markets where growing specialty care, academic research, and clinical trial activity coexist with affordability, reimbursement, and access challenges.

In Europe, the United Kingdom, Germany, and France are central to biomarker research, diagnostics adoption, dementia initiatives, and pharmaceutical partnerships. Italy and Spain contribute through strong neurology networks, aging populations, and clinical trial participation, while Russia has scientific and clinical capacity but faces geopolitical, regulatory, and market access constraints.

In Asia-Pacific, China is scaling biotechnology, AI, genomics, and diagnostics infrastructure; India offers a large patient population and expanding laboratory networks; Japan has a high aging burden and advanced medical technology adoption; Australia supports high-quality clinical research and neurodegenerative disease programs; and South Korea is a strong digital health, imaging, and medtech innovation hub.

Actionable Recommendations for Neurological Biomarker Leaders

Industry leaders should prioritize biomarkers with clear clinical utility, not only analytical performance. The strongest opportunities are in tests that guide therapy selection, confirm disease pathology, identify progression risk, reduce clinical trial screen failures, or monitor treatment response in real-world neurology settings.

Organizations should build evidence packages that include diverse cohorts, longitudinal outcomes, health economic value, and real-world performance. Partnerships with academic centers, biobanks, clinical trial networks, imaging providers, pharmaceutical sponsors, and digital health platforms can accelerate validation, regulatory readiness, and adoption.

Executives should also invest in regulatory strategy, data governance, interoperability, cybersecurity, and payer engagement early. Scalable blood-based assays, AI-enabled imaging workflows, and digital biomarkers should be designed for integration into neurology clinics, memory centers, emergency care, decentralized trials, and remote monitoring programs.

Research Methodology

This executive summary is developed using a secondary research framework focused on verified public sources, peer-reviewed scientific literature, regulatory information, disease burden data, and healthcare infrastructure indicators. Key reference categories include WHO neurological disease statistics, FDA device and diagnostic information, EMA and EU regulatory frameworks, national health agencies, clinical trial registries, and published clinical consensus statements.

The analysis evaluates biomarker modalities including blood, CSF, neuroimaging, electrophysiology, digital biomarkers, genetics, proteomics, and metabolomics. Interpretation emphasizes clinical adoption, regulatory readiness, reimbursement potential, competitive differentiation, regional healthcare capacity, and evidence requirements for precision neurology.

Insights are synthesized to support executive decision-making without presenting unverified market sizing, market share, or forecasts. Where numeric data are included, they reflect publicly reported disease burden or regulatory indicators from recognized sources.

Conclusion

Neurological biomarkers are becoming foundational to precision neurology as healthcare systems seek earlier diagnosis, better patient stratification, and objective monitoring of complex brain disorders. The convergence of blood-based testing, advanced imaging, digital measures, neurophysiology, multi-omics, and artificial intelligence is expanding use cases from research and clinical trials into routine care pathways.

The next phase of adoption will depend on validation, equity, reimbursement, regulatory confidence, and trust. Organizations that combine scientific rigor with scalable deployment, strong data governance, workflow integration, and payer-relevant evidence will be best positioned to lead in the neurological biomarkers landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Neurological Biomarkers Market, by Biomarker Type
7.1. Introduction
7.2. Protein Biomarkers
7.2.1. Tau Proteins
7.2.2. Amyloid-Beta
7.2.3. Neurofilament Light Chain
7.2.4. Alpha-Synuclein
7.3. Genetic Biomarkers
7.3.1. APOE Genotype
7.3.2. Mutations
7.3.3. Copy Number Variations
7.3.4. Microsatellite Markers
7.4. Proteomic Biomarkers
7.5. Metabolic Biomarkers
7.6. Metabolomic Biomarkers
7.7. Oxidative Stress Biomarkers
8. Neurological Biomarkers Market, by Technology Platform
8.1. Introduction
8.2. Enzyme-Linked Immunosorbent Assay
8.3. Imaging Techniques
8.3.1. Computed Tomography
8.3.2. Functional Near-Infrared Spectroscopy
8.3.3. Magnetic Resonance Imaging
8.3.4. Positron Emission Tomography
8.4. Mass Spectrometry
8.5. Next-Generation Sequencing
8.5.1. RNA Sequencing
8.5.2. Targeted Resequencing
8.5.3. Whole Genome Sequencing
8.6. Polymerase Chain Reaction
9. Neurological Biomarkers Market, by Specimen Source
9.1. Introduction
9.2. Cerebrospinal Fluid
9.3. Blood-Based
9.3.1. Serum
9.3.2. Plasma
9.3.3. Whole Blood
9.3.4. Dried Blood Spots
9.4. Urine
9.5. Saliva
10. Neurological Biomarkers Market, by Application
10.1. Introduction
10.2. Diagnostics
10.3. Drug Development
10.4. Monitoring
10.5. Prognostics
10.6. Research
11. Neurological Biomarkers Market, by End User
11.1. Introduction
11.2. Contract Research Organizations
11.3. Diagnostic Laboratories
11.4. Hospitals & Clinics
11.5. Pharmaceutical & Biotechnology Companies
11.6. Research Institutes
12. Neurological Biomarkers Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Neurological Biomarkers Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Neurological Biomarkers Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. Acumen Pharmaceuticals Inc.
16.3. ADx NeuroSciences NV
16.4. Agilent Technologies, Inc.
16.5. Alector Inc.
16.6. Altoida Inc.
16.7. Banyan Biomarkers, Inc.
16.8. Becton, Dickinson and Company
16.9. Bio-Rad Laboratories, Inc.
16.10. Bio-Techne Corporation
16.11. Biogen Inc.
16.12. bioMérieux SA
16.13. Bruker Corporation
16.14. C2N Diagnostics, LLC
16.15. Charles River Laboratories International, Inc.
16.16. CND Life Sciences
16.17. Danaher Corporation
16.18. Eli Lilly and Company
16.19. Euroimmun AG
16.20. F. Hoffmann-La Roche AG
16.21. GE HealthCare Technologies Inc.
16.22. Illumina, Inc.
16.23. Invicro LLC
16.24. Johnson & Johnson Services, Inc.
16.25. Laboratory Corporation of America Holdings
16.26. Merck KGaA
16.27. Myriad Genetics, Inc.
16.28. Qiagen N.V.
16.29. Quanterix Corporation
16.30. Siemens Healthineers AG
List of Figures
FIGURE 1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2032 (%)
FIGURE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL TAU PROTEINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL TAU PROTEINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL TAU PROTEINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL AMYLOID-BETA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL AMYLOID-BETA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL AMYLOID-BETA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL NEUROFILAMENT LIGHT CHAIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL NEUROFILAMENT LIGHT CHAIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL NEUROFILAMENT LIGHT CHAIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ALPHA-SYNUCLEIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ALPHA-SYNUCLEIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ALPHA-SYNUCLEIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL GENETIC BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL GENETIC BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL GENETIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL APOE GENOTYPE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL APOE GENOTYPE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL APOE GENOTYPE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL MUTATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL MUTATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL MUTATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL COPY NUMBER VARIATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL COPY NUMBER VARIATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL COPY NUMBER VARIATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL MICROSATELLITE MARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL MICROSATELLITE MARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL MICROSATELLITE MARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL PROTEOMIC BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL PROTEOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL PROTEOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL METABOLIC BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL METABOLIC BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL METABOLIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL METABOLOMIC BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL METABOLOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL METABOLOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL OXIDATIVE STRESS BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL OXIDATIVE STRESS BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL OXIDATIVE STRESS BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL IMAGING TECHNIQUES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL IMAGING TECHNIQUES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL IMAGING TECHNIQUES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL FUNCTIONAL NEAR-INFRARED SPECTROSCOPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL FUNCTIONAL NEAR-INFRARED SPECTROSCOPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL FUNCTIONAL NEAR-INFRARED SPECTROSCOPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RNA SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL RNA SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL RNA SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL TARGETED RESEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL TARGETED RESEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL TARGETED RESEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL BLOOD-BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL BLOOD-BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL BLOOD-BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL SERUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL SERUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL PLASMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL WHOLE BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL WHOLE BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL WHOLE BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL DRIED BLOOD SPOTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL DRIED BLOOD SPOTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL DRIED BLOOD SPOTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL URINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL URINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL SALIVA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL DRUG DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL DRUG DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL DRUG DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL PROGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL PROGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL PROGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL RESEARCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL RESEARCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL RESEARCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 152. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 154. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 155. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 156. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 157. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 158. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 159. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 160. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 161. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 162. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 165. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 166. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 167. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 168. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 169. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 170. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 171. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 172. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 173. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 176. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 177. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 180. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 181. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 182. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 183. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 184. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 185. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 186. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 187. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 188. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 189. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 190. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 191. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 192. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 193. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 194. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 195. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 197. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 198. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 199. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 200. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 201. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 202. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 203. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 204. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 205. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 206. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 208. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 209. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 210. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 211. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 212. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 213. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 214. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 215. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 216. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 217. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 218. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 219. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 220. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 221. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 222. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 223. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 224. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 225. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 226. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 227. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 228. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 229. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 230. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 231. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 232. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 233. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 234. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 235. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 236. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 237. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 238. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 239. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 240. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 253. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 254. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 255. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 256. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 257. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 258. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 259. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 260. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 261. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 262. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 264. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 265. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 266. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 267. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 268. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 269. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 270. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 271. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 272. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 273. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 274. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 275. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 276. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 277. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 278. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 279. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 280. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 281. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 282. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 283. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 284. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 285. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 286. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 288. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 289. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 290. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 291. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 292. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 293. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 294. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 295. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 296. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 297. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 298. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 299. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 300. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 301. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 302. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 303. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 304. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 305. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 306. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 307. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 308. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 309. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 310. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 311. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 312. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 313. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 314. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 315. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 316. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 317. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 318. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 319. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 320. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 321. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 322. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 323. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 324. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 325. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 326. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 327. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 328. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 329. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 330. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 331. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 332. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 333. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 334. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 335. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 336. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 337. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2017-2032 (USD MILLION)
TABLE 338. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2017-2032 (USD MILLION)
TABLE 339. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 340. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 341. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 342. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 343. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 344. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 345. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 346. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2017-2032 (USD MILLION)
TABLE 347. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 348. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE

Companies Mentioned

  • Abbott Laboratories
  • Acumen Pharmaceuticals Inc.
  • ADx NeuroSciences NV
  • Agilent Technologies, Inc.
  • Alector Inc.
  • Altoida Inc.
  • Banyan Biomarkers, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biogen Inc.
  • bioMérieux SA
  • Bruker Corporation
  • C2N Diagnostics, LLC
  • Charles River Laboratories International, Inc.
  • CND Life Sciences
  • Danaher Corporation
  • Eli Lilly and Company
  • Euroimmun AG
  • F. Hoffmann-La Roche AG
  • GE HealthCare Technologies Inc.
  • Illumina, Inc.
  • Invicro LLC
  • Johnson & Johnson Services, Inc.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Qiagen N.V.
  • Quanterix Corporation
  • Siemens Healthineers AG

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 9.88 Billion
Forecasted Market Value ( USD ) by 2032 $ 21.74 Billion
Compound Annual Growth Rate13.9%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Brain Biomarkers Market - Global Forecast 2026-2032 - Product Image

Brain Biomarkers Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Immunoassay for Neurological Biomarkers - Global Strategic Business Report - Product Image

Immunoassay for Neurological Biomarkers - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Neurological Biomarkers Market Size, Share, Trends and Forecast by Type, Application, End Use, and Region, 2026-2034 - Product Image

Neurological Biomarkers Market Size, Share, Trends and Forecast by Type, Application, End Use, and Region, 2026-2034

  • Report
  • 140 Pages
  • Global
From
Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases - Global Strategic Business Report - Product Image

Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Immunoassay for Neurological Biomarkers Market Size, Share & Trends Analysis Report by Product, Disease, Application, Region, and Segment Forecasts, 2026-2033 - Product Image

Immunoassay for Neurological Biomarkers Market Size, Share & Trends Analysis Report by Product, Disease, Application, Region, and Segment Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.